加载中
JPXHealthcareMedical - Diagnostics & Research
最新数据
JP¥3,775
+JP¥50.00 · +1.34%
BML, Inc. is a Japanese corporation specializing in a comprehensive range of laboratory diagnostics and related services. The company conducts standard analyses such as biochemical and hematological screenings, in addition to advanced specialized tests including radioimmunoassay (RIA), cellular diagnostics, immunology, and DNA analysis. It also provides microbiological assessments for medical and pharmaceutical organizations, along with diagnostic services covering critical areas like oncology, infectious diseases, metabolic disorders (diabetes, hypertension), allergies, and genetic studies. To optimize laboratory operations, BML develops proprietary automation systems, Frontier and Symphony, designed to streamline processes from initial sample sorting and dispensing through to subsequent testing. The firm also supports medical information networking via electronic health records and offers preventative healthcare solutions. BML's extensive service portfolio includes food safety and environmental health. Its food division provides comprehensive hygiene control and processing support, encompassing contractual microbiological testing for raw ingredients, prepared, and processed foods. This extends to environmental hygiene assessments for food facilities and kitchens, general microorganism testing, and the evaluation of genetically modified organisms. Environmental services comprise drinking water and wastewater analysis, occupational health management (measuring airborne substances like ethylene oxide, formaldehyde, organic solvents, and dust), comprehensive indoor environmental monitoring (identifying contaminants and other variables), and biological dioxin surveillance. Moreover, BML performs analyses for residual agricultural chemicals, offers dental diagnostics for caries and periodontal diseases, provides consulting for pharmaceutical product approvals, conducts investigative analyses for drug manufacturers, and performs gene expression analysis, specifically identifying genes linked to infectious disease susceptibility. Founded in 1955, BML, Inc. is headquartered in Tokyo, Japan.
最新数据
JP¥3,775
+JP¥50.00 · +1.34%
盘中时间采用JST。市场数据可能有所延迟。
BML, Inc. is a Japanese corporation specializing in a comprehensive range of laboratory diagnostics and related services. The company conducts standard analyses such as biochemical and hematological screenings, in addition to advanced specialized tests including radioimmunoassay (RIA), cellular diagnostics, immunology, and DNA analysis. It also provides microbiological assessments for medical and pharmaceutical organizations, along with diagnostic services covering critical areas like oncology, infectious diseases, metabolic disorders (diabetes, hypertension), allergies, and genetic studies. To optimize laboratory operations, BML develops proprietary automation systems, Frontier and Symphony, designed to streamline processes from initial sample sorting and dispensing through to subsequent testing. The firm also supports medical information networking via electronic health records and offers preventative healthcare solutions. BML's extensive service portfolio includes food safety and environmental health. Its food division provides comprehensive hygiene control and processing support, encompassing contractual microbiological testing for raw ingredients, prepared, and processed foods. This extends to environmental hygiene assessments for food facilities and kitchens, general microorganism testing, and the evaluation of genetically modified organisms. Environmental services comprise drinking water and wastewater analysis, occupational health management (measuring airborne substances like ethylene oxide, formaldehyde, organic solvents, and dust), comprehensive indoor environmental monitoring (identifying contaminants and other variables), and biological dioxin surveillance. Moreover, BML performs analyses for residual agricultural chemicals, offers dental diagnostics for caries and periodontal diseases, provides consulting for pharmaceutical product approvals, conducts investigative analyses for drug manufacturers, and performs gene expression analysis, specifically identifying genes linked to infectious disease susceptibility. Founded in 1955, BML, Inc. is headquartered in Tokyo, Japan.
日内区间
当前JP¥3,775
52周区间
当前JP¥3,775
盘中时间采用JST。市场数据可能有所延迟。
BML, Inc. is a Japanese corporation specializing in a comprehensive range of laboratory diagnostics and related services. The company conducts standard analyses such as biochemical and hematological screenings, in addition to advanced specialized tests including radioimmunoassay (RIA), cellular diagnostics, immunology, and DNA analysis. It also provides microbiological assessments for medical and pharmaceutical organizations, along with diagnostic services covering critical areas like oncology, infectious diseases, metabolic disorders (diabetes, hypertension), allergies, and genetic studies. To optimize laboratory operations, BML develops proprietary automation systems, Frontier and Symphony, designed to streamline processes from initial sample sorting and dispensing through to subsequent testing. The firm also supports medical information networking via electronic health records and offers preventative healthcare solutions. BML's extensive service portfolio includes food safety and environmental health. Its food division provides comprehensive hygiene control and processing support, encompassing contractual microbiological testing for raw ingredients, prepared, and processed foods. This extends to environmental hygiene assessments for food facilities and kitchens, general microorganism testing, and the evaluation of genetically modified organisms. Environmental services comprise drinking water and wastewater analysis, occupational health management (measuring airborne substances like ethylene oxide, formaldehyde, organic solvents, and dust), comprehensive indoor environmental monitoring (identifying contaminants and other variables), and biological dioxin surveillance. Moreover, BML performs analyses for residual agricultural chemicals, offers dental diagnostics for caries and periodontal diseases, provides consulting for pharmaceutical product approvals, conducts investigative analyses for drug manufacturers, and performs gene expression analysis, specifically identifying genes linked to infectious disease susceptibility. Founded in 1955, BML, Inc. is headquartered in Tokyo, Japan.
日内区间
当前JP¥3,775
52周区间
当前JP¥3,775
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（JPY） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1502.62亿 JPY | 1431.91亿 JPY | 1379.64亿 JPY | 1594.62亿 JPY | 1860.67亿 JPY |
| 销货成本 | 1015.72亿 JPY | 973.29亿 JPY | 923.35亿 JPY | 980.16亿 JPY | 991.16亿 JPY |
| 毛利 | 486.9亿 JPY | 458.62亿 JPY | 456.29亿 JPY | 614.46亿 JPY | 869.51亿 JPY |
| 研究与开发 | — | 2.6亿 JPY | 2.75亿 JPY | 2.71亿 JPY | 3.02亿 JPY |
| 销售、一般及管理费用 | 382.67亿 JPY | 362.37亿 JPY | 361.86亿 JPY | 372.38亿 JPY | 377.59亿 JPY |
| 营业费用 | 382.67亿 JPY | 364.97亿 JPY | 364.61亿 JPY | 375.09亿 JPY | 380.61亿 JPY |
| 利息收入 | 1.06亿 JPY | — | — | — | — |
| 利息支出 | 1.19亿 JPY | 1.18亿 JPY | 1.04亿 JPY | 4000万 JPY | 3600万 JPY |
| 折旧和摊销 | 91.21亿 JPY | 77.16亿 JPY | 67.91亿 JPY | 63.48亿 JPY | 58.92亿 JPY |
| 营业利润 | 104.23亿 JPY | 93.65亿 JPY | 91.68亿 JPY | 239.37亿 JPY | 488.9亿 JPY |
| 净利润 | 77.48亿 JPY | 62.64亿 JPY | 60.35亿 JPY | 155.78亿 JPY | 337.41亿 JPY |
公司数据更新于 2026年10月14日。
近期已公布业绩
近期已公布业绩
年度分割调整后的每股现金分配。
JP¥130
2025年（完整年度）+52.9% 自从 2021
2026年（部分年度）：JP¥127.5
JP¥85.00
2,021
JP¥125
2,022
JP¥100
2,023
JP¥90.00
2,024
JP¥130
2,025
JP¥127.5
2,026*
* 在现有股息历史记录中，该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息即将实施 | 2027年3月30日 | JP¥62.50Semi-Annual | 2027年3月31日 | 2027年3月30日 |
股息 | 2026年9月29日 | JP¥62.50Semi-Annual | 2026年9月30日 | 2026年9月29日 |
股息 | 2026年3月30日 | JP¥65.00Semi-Annual | 2026年3月31日 | 2026年6月29日 |
股息 | 2025年9月29日 | JP¥60.00Annual | 2025年9月30日 | 2025年12月2日 |
股息 | 2025年3月28日 | JP¥70.00Special | 2025年3月31日 | 2025年6月30日 |
股息 | 2024年9月27日 | JP¥50.00Semi-Annual | 2024年9月30日 | 2024年12月3日 |
除息 2027年3月30日
JP¥62.50
Semi-Annual
2027年3月31日登记 · 支付日 2027年3月30日
除息 2026年9月29日
JP¥62.50
Semi-Annual
2026年9月30日登记 · 支付日 2026年9月29日
除息 2026年3月30日
JP¥65.00
Semi-Annual
2026年3月31日登记 · 支付日 2026年6月29日
除息 2025年9月29日
JP¥60.00
Annual
2025年9月30日登记 · 支付日 2025年12月2日
除息 2025年3月28日
JP¥70.00
Special
2025年3月31日登记 · 支付日 2025年6月30日
除息 2024年9月27日
JP¥50.00
Semi-Annual
2024年9月30日登记 · 支付日 2024年12月3日
报告持有此股票敞口的交易所交易基金。
NEXT FUNDS TOPIX Exchange Traded Fund1306.T30.24亿0.01%35.17万亿 JPY0.05%JP¥431.3-0.28%
iShares Core TOPIX ETF1475.T2.69亿0.01%3.01万亿 JPY0.05%JP¥425-0.21%
Vanguard Total International Stock ETFVXUS696.78万0.00%6657亿 USD0.05%US$84.54+0.12%
Avantis International Small Cap Value ETFAVDV512.57万0.03%199.2亿 USD0.36%US$108.58+0.51%
Vanguard FTSE Developed Markets ETFVEA449.31万0.00%3238亿 USD0.03%US$70.06+0.16%
iShares Core MSCI EAFE ETFIEFA303.83万0.00%1889.44亿 USD0.07%US$96.64+0.48%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS171.25万0.01%145亿 USD0.06%US$154.25+0.07%
iShares MSCI EAFE Small-Cap ETFSCZ153.91万0.01%128.31亿 USD0.40%US$83.95+0.39%NEXT FUNDS TOPIX Exchange Traded Fund1306.TiShares Core TOPIX ETF1475.TVanguard Total International Stock ETFVXUSAvantis International Small Cap Value ETFAVDVVanguard FTSE Developed Markets ETFVEAiShares Core MSCI EAFE ETFIEFAVanguard FTSE All-World ex-US Small-Cap ETFVSSiShares MSCI EAFE Small-Cap ETFSCZAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
